Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.60
<$0.01(0.05%)
At close: 4:00 PM EST
$0.60
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$16.43M
Enterprise Value$5.11M
Total Cash (Recent Filing)$8.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 18, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding15,798,031
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-729.48
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$10.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory: FDA Safety ClearanceThe FDA's lack of comments on the amended protocol and interim safety data materially reduces regulatory execution risk for Auxora. This enduring safety confirmation supports continued enrollment, preserves program value across indications, and improves potential for eventual pivotal trial design and partnerships.
Extended Runway Via FinancingThe upfront financing materially extends operational runway into 2H-2027, allowing execution of Phase 1b and IND-enabling work without immediate capital stress. A multi-quarter runway reduces near-term financing urgency and supports measured development decisions and partner discussions.
Lower Reported LeverageA zero reported debt balance in the trailing twelve months reduces fixed financing obligations and interest burden, improving financial flexibility. Lower leverage increases strategic optionality for funding clinical programs and negotiating non-dilutive collaborations over the medium term.
Bears Say
Pre-revenue With High Cash BurnThe company is pre-revenue and consistently consumes roughly $21M annually in operating cash, creating structural funding dependence. Without commercialization or partner milestones, the sustained burn necessitates repeated capital raises, which can delay programs and dilute long-term shareholder returns.
Negative Stockholders' EquityNegative equity signals cumulative losses and eroded capital cushions, constraining the company's ability to access non-dilutive funding and increasing creditor and investor scrutiny. This structural weakness limits strategic flexibility and raises the bar for clinical or partnership successes to restore balance sheet health.
Dilution Risk From Financing TermsAmended loan conversion rights plus repriced and newly issued warrants create meaningful potential equity dilution and cap ownership scenarios. Over time this can reduce existing holders' upside, complicate governance, and pressure per-share economics unless clinical readouts or non-dilutive partnerships materially de-risk the programs.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $16.43M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on May 12, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.58.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.29.
How many shares outstanding does CalciMedica have?
CalciMedica has 15,798,031 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of $0.3 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 6.599%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1566.67% Upside)
Technical Analysis
Ownership Overview
43.49% Insiders
1.58% Mutual Funds
1.46% Other Institutional Investors
52.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---